A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia
Latest Information Update: 08 Jun 2025
At a glance
- Drugs Zanubrutinib (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Registrational; Therapeutic Use
- Sponsors BeOne Medicines
Most Recent Events
- 20 Sep 2023 Status changed from not yet recruiting to recruiting.
- 31 Aug 2023 Planned initiation date changed from 31 Jul 2023 to 29 Sep 2023.
- 03 Jul 2023 Planned initiation date changed from 30 Jun 2023 to 31 Jul 2023.